Guardant Health Inc. (GH)
NASDAQ: GH · Services-Medical Laboratories · Palo Alto, CA
Our rating: Positive
Call changed from Cautious to Positive at $150.87, moderate conviction, November 6, 2026.
Breaks if: The Positive call breaks if Guardant reports revenue growth below 20% year-over-year in two consecutive quarterly filings — that would signal Shield adoption has plateaued and the core oncology monitoring business cannot compensate, removing the rationale for a premium multiple. The call also breaks if the annual free cash flow deficit widens beyond $350M over the next four quarters, indicating that spending is outrunning the revenue ramp and pushing the already-invisible profit horizon further out of reach.
Key figures
| Market value | $19.7B |
|---|---|
| Revenue, last 12 months | $1.3B |
| Net income, last 12 months | −$485M |
| Free cash flow, last 12 months | −$232M |
| Price to earnings | n/a |
| Free cash flow yield | −1.2% |
| Dividend yield | 0.0% |
| Operating margin | −39.4% |
| Return on equity | n/a |
| Beta to the S&P 500 | 1.18 |
| Volatility, annualized | 61.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $361M | 36.1% | $-0.93 | −$37M |
| June 30, 2026 | $335M | 44.3% | $-0.90 | −$70M |
| March 31, 2026 | $302M | 48.3% | $-0.85 | −$71M |
| December 31, 2025 | $281M | 39.4% | $-1.00 | −$54M |
| September 30, 2025 | $265M | 38.5% | $-0.74 | −$46M |
| June 30, 2025 | $232M | 30.9% | $-0.80 | −$66M |
| March 31, 2025 | $203M | 20.8% | $-0.77 | −$67M |
| December 31, 2024 | $202M | 30.2% | $-0.90 | −$83M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.40B: Claude 72%, Gemini 35%, Mistral 42%
- Diluted earnings per share are above zero: Claude 4%, Gemini 2%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 25%, Gemini 12%, Mistral 10%
18 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.